Search

Displaying results 3331 - 3340 of 10000 in total
  1. Drug

    Estradiol dienanthate

    go.drugbank.com/drugs/DB13955
    ApprovedVet approvedWithdrawn

    As a pro-drug of estradiol, estradiol benzoate therefore has the same downstream effects within the body through binding to the Estrogen Receptor (ER) including ERα and ERβ subtypes, which are located … First-pass metabolism by the gut and the liver quickly degrades the estradiol molecule before it gets a chance to enter systemic circulation and exert its estrogenic effects [A12102].

  2. Drug

    Aripiprazole

    go.drugbank.com/drugs/DB01238
    ApprovedInvestigational

    Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor Agonists
  3. Drug

    Gliquidone

    go.drugbank.com/drugs/DB01251
    Approved

    Gliquidone is a sulfonylurea drug used to treat diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. … This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.

  4. Drug

    Urokinase

    go.drugbank.com/drugs/DB00013
    ApprovedInvestigationalWithdrawn

    Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase.

    Products: Kinlytic Open-cath
  5. Drug

    Patiromer

    go.drugbank.com/drugs/DB09263
    ApprovedInvestigational

    Each gram of patiromer is equivalent to a nominal amount of 2 grams of patiromer sorbitex calcium. … Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015.

  6. Drug

    Daraxonrasib

    go.drugbank.com/drugs/DB22308
    ApprovedInvestigational

    Daraxonrasib is an orally administered, multi-selective inhibitor of the RAS GTPase family used to treat metastatic pancreatic adenocarcinoma. … [L64039,L64040] It is the first targeted cancer medicine approved from the class of RAS(ON) multi-selective and mutant-selective inhibitors.[L64041]

  7. Drug

    Rolapitant

    go.drugbank.com/drugs/DB09291
    ApprovedInvestigational

    By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. … late-phase CINV during the first 120 hours post-chemotherapy.

    Categories: Neurokinin-1 Receptor Antagonists, Substance P/Neurokinin-1 Receptor Antagonist
  8. Drug

    Teriflunomide

    go.drugbank.com/drugs/DB08880
    ApprovedInvestigational

    It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. … The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.

  9. Drug

    Ripasudil

    go.drugbank.com/drugs/DB13165
    Investigational

    This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec. … Ripasudil is a well tolerated medication that is used when other drugs have been proven to be non-effective or cannot be administered.

  10. Drug

    Atosiban

    go.drugbank.com/drugs/DB09059
    ApprovedInvestigational

    Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor. … Atobisan was developed by the Swedish company Ferring Pharmaceuticals. It was first reported in the literature in 1985.